Actinium Pharmaceuticals (ATNM)
(Real Time Quote from BATS)
$7.94 USD
+0.20 (2.58%)
Updated Jul 25, 2024 11:16 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATNM 7.94 +0.20(2.58%)
Will ATNM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATNM
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
ATNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue Estimates
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
Other News for ATNM
Actinium wins FDA nod to conduct clinical trial for radiotherapy
Actinium Pharmaceuticals' IND application in sickle cell disease approved by FDA
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
Buy Rating Reiterated for Actinium Pharmaceuticals Amid Promising AML Therapy Developments